By comparing the target proteins (TPs) of classic traditional Chinese medicine (TCM) herbal formulas and modern drugs used for treating coronary artery disease (CAD), this study aimed to identify potential therapeutic TPs for treating CAD. Based on the theory of TCM, the Xuefu-Zhuyu decoction (XZD) and Gualou-Xiebai-Banxia decoction (GXBD), both of which are classic herbal formulas, were selected for treating CAD. Data on the chemical ingredients and corresponding TPs of the herbs in these two formulas and data on modern drugs approved for treating CAD and related TPs were retrieved from professional TCM and bioinformatics databases. Based on the associations between the drugs or ingredients and their TPs, the TP networks of XZD, GXBD, and modern drugs approved for treating CAD were constructed separately and then integrated to create a complex master network in which the vertices represent the TPs and the edges, the ingredients or drugs that are linked to the TPs. The reliability of this master network was validated through statistical tests. The common TPs of the two herbal formulas have a higher possibility of being targeted by modern drugs in comparison with the formula-specific TPs. A total of 114 common XZD and GXBD TPs that are not yet the target of modern drugs used for treating CAD should be experimentally investigated as potential therapeutic targets for treating CAD. Among these TPs, the top 10 are NOS3, PTPN1, GABRA1, PRKACA, CDK2, MAOB, ESR1, ADH1C, ADH1B, and AKR1B1. The results of this study provide a valuable reference for further experimental investigations of therapeutic targets for CAD. The established method shows promise for searching for potential therapeutic TPs based on herbal formulas. It is crucial for this work to select beneficial therapeutic targets of TCM, typical TCM syndromes, and corresponding classic formulas.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300118 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0171628 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
A retrospective study of reported adverse events associated with cardiac stents in Indian population.
Expert Rev Med Devices
January 2025
Faculty of Pharmacy, VNS Group of Institutions, Bhopal, Madhya Pradesh, India.
Background: Cardiac stents are utilized to treat coronary artery diseases, a leading cause of death worldwide including in India. We investigated frequency and nature of adverse events (AEs) associated with cardiac stents in the Indian population.
Methods: The source data was systematically collected by National Coordination Centre -Materiovigilance programme of India (NCC-MvPI), anonymized from 2020 to 2022.
Exploring parenthood intentions and perceptions of infertility and assisted reproductive technology among 2SLGBTQIA + young adults in Ontario, Canada: a mixed methods study.
J Health Popul Nutr
January 2025
Faculty of Health Sciences, Interdisciplinary School of Health Sciences, University of Ottawa, 25 Université Priv, Ottawa, K1N 6N5, Canada.
Background: As Generation Z two-spirit, lesbian, gay, bisexual, transgender/trans, queer, intersex, asexual and others who identify as part of sexual and gender diverse communities (2SLGBTQIA +) enter adulthood, contemplation of family creation may be challenged by biological and/or social infertility. Despite some advances in societal acceptance of gender and sexual minorities, family planning and reproductive healthcare remain heteronormative. To explore reproductive decision-making and how future families are conceptualized across genders, we evaluated perceptions of Ontario, Canada non-parenting, 2SLGBTQIA + emerging adults.
View Article and Find Full Text PDFChanges in microcirculation following transcatheter aortic valve implantation in patients with stable coronary artery disease.
Arch Cardiovasc Dis
December 2024
Nantes Université, CHU Nantes, Unité Hémodynamique et Cardiologie Interventionnelle, l'institut du thorax, 44000 Nantes, France.
Background: Few studies have assessed coronary physiology in the setting of coronary artery disease (CAD) with severe aortic stenosis (AS). Fractional flow reserve (FFR) to guide revascularization in such patients is not validated.
Aims: We describe changes in coronary physiology in this population before and after transcatheter aortic valve implantation (TAVI).
Beta-Blockers After PCI for Stable Coronary Artery Disease and Preserved Left Ventricular Ejection Fraction.
JACC Adv
January 2025
Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA.
Background: Limited data exist on the long-term impact of beta-blocker therapy after percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD) and preserved left ventricular ejection fraction (LVEF).
Objectives: The aim of the study was to evaluate the effects of early beta-blocker initiation vs no initiation following PCI in patients with stable CAD and preserved LVEF.
Methods: This retrospective cohort study employed target trial emulation and incident user design, utilizing the TriNetx database (2009-2024).
The Effect of Colchicine on Platelet Function Profiles in Patients with Stable Coronary Artery Disease: The ECLIPSE Pilot Study.
Cardiol Ther
January 2025
Adult Medicine, Department of Clinical Medical Sciences, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago.
Introduction: This prospective, single-arm pharmacodynamic study assessed the effect of colchicine (COLC) [Strides Pharma UK Ltd, Watford, Hertfordshire, England] 0.5 mg administered orally once daily for 14 days on platelet reactivity with respect to aspirin reaction units (ARUs) and P2Y reaction units (PRUs).
Methods: Twenty-two patients with stable coronary artery disease (CAD) on dual antiplatelet therapy (DAPT) with daily maintenance aspirin and clopidogrel were recruited.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!